ChiCTR2200059423 版本V1.0 版本创建时间2023/02/07 11:13:28 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200059423 

最近更新日期:

Date of Last Refreshed on:

2022-04-29 06:53:05 

注册时间:

Date of Registration:

2022-04-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

fMRI引导的精准定位rTMS对于帕金森震颤症状的治疗

Public title:

Precise localization of rTMS guided by fMRI for the treatment of Parkinson's tremor

注册题目简写:

English Acronym:

研究课题的正式科学名称:

fMRI引导的精准定位rTMS对于帕金森震颤症状的治疗

Scientific title:

Precise localization of rTMS guided by fMRI for the treatment of Parkinson's tremor

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王宏潇 

研究负责人:

臧玉峰 

Applicant:

Hongxiao Wang 

Study leader:

Yufeng Zang 

申请注册联系人电话:

Applicant telephone:

13388611573

研究负责人电话:

Study leader's
telephone:

18606517380

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

279848601@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zangyf@hznu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国浙江省杭州市余杭区余杭塘路2318号杭州师范大学

研究负责人通讯地址:

中国浙江省杭州市余杭区余杭塘路2318号杭州师范大学

Applicant address:

NO.2318, Yuhangtang Rd, Yuhang District, 311121, Hangzhou, Zhejiang, P.R.China

Study leader's address:

NO.2318, Yuhangtang Rd, Yuhang District, 311121, Hangzhou, Zhejiang, P.R.China

申请注册联系人邮政编码:

Applicant postcode:

311100

研究负责人邮政编码:

Study leader's postcode:

311100

申请人所在单位:

杭州师范大学

Applicant's institution:

Hangzhou Normal University

研究负责人所在单位:

杭州师范大学

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20222(E2)-HS-013

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

杭州师范大学附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, The Affiliated Hospital of Hangzhou Normal University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-01-13 00:00:00

伦理委员会联系人:

干文韬

Contact Name of the ethic committee:

+86-13867415205

伦理委员会联系地址:

杭州市拱墅区温州路126号杭州师范大学附属医院

Contact Address of the ethic committee:

NO.126,Wenzhou Rd, Gongshu District, 310015, Hangzhou, Zhejiang, P.R.China

伦理委员会联系人电话:

Contact phone of the ethic committee:

0571-88303417

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

杭州师范大学

Primary sponsor:

Hangzhou Normal University

研究实施负责(组长)单位地址:

中国浙江省杭州市余杭区余杭塘路2318号杭州师范大学

Primary sponsor's address:

NO.2318, Yuhangtang Rd, Yuhang District, 311121, Hangzhou, Zhejiang, P.R.China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

杭州师范大学附属医院

具体地址:

拱墅区温州路126号

Institution
hospital:

The Affiliated Hospital of Hangzhou Normal University

Address:

126 Wenzhou Road, Gongshu District

经费或物资来源:

国家自然科学基金

Source(s) of funding:

National Natural Science Foundation of China

研究疾病:

帕金森  

Target disease:

Parkinson's disease

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

寻找TMS治疗帕金森震颤症状的最佳刺激靶点  

Objectives of Study:

To search for the best stimulation target of TMS for Parkinson's tremor

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)符合帕金森病的诊断标准;(2)H-Y 分级≤ 4 级;(3) FTMTRS A 部分第 4 项得分≤2,FTMTRS A 部分第 5、6 项得分≥1;(4)发病 年龄 40 岁以上,症状持续 1 年以上,且一个月内未调药物方案;(5)能接受 TMS 疗 法,本人及监护人同意按照本研究治疗和观察者。(6)能顺利完成 fMRI 扫描,且进行 数据分析时(两人分析,进行交叉验证)头动不超过 5 毫米 5 度。

Inclusion criteria

(1) Meet the diagnostic criteria of Parkinson's disease;(2) H-Y ≤ 4;(3) Score of item 4 in FTMTRS Part A ≤2, score of item 5 and 6 in FTMTRS Part A ≥1;(4) The onset age was more than 40 years old, symptoms lasted for more than one year, and no drug regimen was adjusted within one month;(5) Can accept TMS therapy, I and my guardian agree to the treatment and observer according to this study.(6) fMRI scan can be successfully completed, and the head movement during data analysis (two-person analysis, cross-validation) is no more than 5 mm 5 degrees.

排除标准:

(1)有严重脑器质性疾病,如癫痫、脑卒中、脑炎、脑外伤等,或者 存在严重躯体疾病如恶性肿瘤、急性心衰、多器官衰竭等;(2)有精神疾病、酒精和药 物依赖史;(3)胸部以上,尤其是颅内或心脏,放置有金属植入物者;(4)妊娠期或哺 乳期女性;

Exclusion criteria:

(1) serious organic brain diseases, such as epilepsy, stroke, encephalitis, brain trauma, etc., or serious physical diseases, such as malignant tumor, acute heart failure, multiple organ failure, etc.;(2) a history of mental illness, alcohol or drug dependence;(3) those with metal implants above the chest, especially inside the skull or heart;(4) pregnant or breastfeeding women;

研究实施时间:

Study execute time:

From 2022-04-27 00:00:00 To 2024-06-27 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-04-27 00:00:00 To 2024-06-01 00:00:00

干预措施:

Interventions:

组别:

1组

样本量:

15

Group:

Group 1

Sample size:

干预措施:

患侧STN、GPi功能连接最强的皮层位点进行刺激

干预措施代码:

Intervention:

Stimulate the cortical site with the strongest functional connection of STN and GPi on the affected side

Intervention code:

组别:

2组

样本量:

15

Group:

Group 2

Sample size:

干预措施:

在传统定位的刺激靶点手部Hotspot (M1)进行刺激

干预措施代码:

Intervention:

Stimulate the hand Hotspot (M1) at the traditionally positioned stimulation target

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

杭州 

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

杭州师范大学附属医院 

单位级别:

三甲 

Institution
hospital:

The Affiliated Hospital of Hangzhou Normal University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机对照试验

Randomization Procedure (please state who generates the random number sequence and by what method):

Non randomized control

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

邮件

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Email

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-04-29 06:53:05